This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (13)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Diabetic Retinopathy  • Ophthalmological Procedures, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Francesco Bandello, MD; Antonio Polito, MD; Derri Roman Pognuz, MD; Pietro Monaco, MD; Andrea Dimastrogiovanni, MD; Joannis Paissios, MD

Arch Ophthalmol. 2006;124:643-650.

Objective  To evaluate intravitreal injection of triamcinolone acetonide before laser panretinal photocoagulation (PRP) in the treatment of proliferative diabetic retinopathy.

Methods  This interventional case series included 9 patients with bilateral proliferative diabetic retinopathy. One eye received intravitreal triamcinolone before PRP (injected eye) and the other, PRP alone (control eye). The main outcome measures were the change in planimetric area of fluorescein leakage from retinal neovascularization and in central macular thickness on optical coherence tomography at 3, 6, 9, and 12 months. Secondary end points were change in vision, intraocular pressure, and cataract progression.

Results  All patients completed 9 months and 5 patients, 12 months of follow-up. Initial mean (SD) planimetric area of fluorescein leakage and central macular thickness were 7.22 (5.70) mm² and 372.11 (91.88) µm in injected eyes and 9.08 (6.17) mm² and 355.33 (115.23) µm in control eyes, respectively. At the 9- and 12-month intervals, the planimetric area of fluorescein leakage decreased by 86% and 88% in injected eyes and 33% and 50% in controls, respectively. Central macular thickness significantly decreased in injected eyes and increased in control eyes. Vision slightly improved in injected eyes and worsened in control eyes.

Conclusion  Intravitreal injection of triamcinolone before PRP may be useful in improving the effects of PRP in eyes with proliferative diabetic retinopathy by reducing neovascularization and macular thickening.

Author Affiliations: Department of Ophthalmology, University of Udine, Piazzale Santa Maria della Misericordia, Udine, Italy.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Randomised controlled trial of posterior sub-Tenon triamcinolone as adjunct to panretinal photocoagulation for treatment of diabetic retinopathy
Unoki et al.
Br. J. Ophthalmol. 2009;93:765-770.
ABSTRACT | FULL TEXT  

Cytotoxicity of Triamcinolone Acetonide on Human Retinal Pigment Epithelial Cells
Chang et al.
IOVS 2007;48:2792-2798.
ABSTRACT | FULL TEXT